Introduction
The monoaminergic neurotransmitter dopamine (DA) has been implicated in multiple brain disorders, including schizophrenia, affective disorders, addiction, and Parkinson's disease (Snyder, 1976; Carlsson, 1987; Gainetdinov and Caron, 2003) . In the brain, the main dopaminergic neuron population arises from the substantia nigra pars compacta and projects to striatal neurons. Two subclasses of G-protein-coupled receptors (GPCRs) mediate the various physiological functions of DA (Kebabian and Calne, 1979) . D 1 -class receptors (D 1 and D 5 subtypes) are mostly coupled to G␣ s and enhance the production of cAMP, whereas D 2 -class receptors (D 2 , D 3 , and D 4 subtypes) are coupled to G␣ i/o and inhibit this same process (Kebabian and Greengard, 1971; Enjalbert and Bockaert, 1983; Missale et al., 1998) . Moreover, an alternate splicing of the D 2 receptor mRNA leads to the expression of two D 2 receptor isoforms, the D 2 short (D 2 S) and D 2 long (D 2 L), which have been associated with presynaptic and postsynaptic D 2 receptor functions, respectively (Giros et al., 1989; Monsma et al., 1989; Usiello et al., 2000; Lindgren et al., 2003) .
Recent in vivo studies revealed that striatal D 2 -class receptors also exert their action in a cAMP-independent manner by promoting the formation of a signaling complex composed of Akt, protein phosphatase-2A (PP2A), and ␤-arrestin 2 (Beaulieu et al., 2004 (Beaulieu et al., , 2005 . Formation of this complex leads to the inactivation of Akt after the dephosphorylation of its regulatory threonine 308 (Thr-308) residue by PP2A (Beaulieu et al., 2005) . Inactivation of Akt in response to DA results in the activation of glycogen synthase kinase 3 (GSK3), which in turn contributes to the expression of DA-associated behaviors (Beaulieu et al., 2004) . Interestingly, reduced Akt functions have been reported in schizophrenic patients, whereas administration of the antipsychotic haloperidol, a D 2 -class receptor antagonist, activates Akt and inhibits GSK3 in the mouse brain (Emamian et al., 2004) . However, the characterization of Akt and GSK3 regulation by DA receptors has remained limited to the use of pharmacological agents that do not allow the delineation of individual roles played by specific subtypes of DA receptors in this process (Beaulieu et al., 2004; Emamian et al., 2004 
Materials and Methods
Experimental animals. D 1 receptor knock-out (D 1 -KO) (Drago et al., 1994) , D 2 receptor knock-out (D 2 -KO) (Baik et al., 1995) , D 2 L receptor knock-out (D 2 L-KO) (Usiello et al., 2000) , D 3 receptor knock-out (D 3 -KO) (Joseph et al., 2002) , DA transporter knock-out (DAT-KO) (Giros et al., 1996; Cyr et al., 2003) , and their respective wild-type (WT) littermates have been described previously. All mice used were from 3 to 4 months of age. For all experiments, test and control groups were composed of age-and sex-matched animals with ϳ50% mice from each sex. Animals were housed four or five to a cage at 23°C on a 12 h light/dark cycle with ad libitum access to food and water. Animal care was approved by the Institutional Animal Care and Use Committee and followed National Institutes of Health guidelines.
Drug administration. Amphetamine (Sigma, St. Louis, MO) and L745870 (Tocris Cookson, Ellisville, MO) were dissolved in saline and injected intraperitoneally. Apomorphine (Sigma) was dissolved in distilled water containing 0.1% ascorbate and injected subcutaneously. Corresponding vehicle solutions were administered to control animals.
Western blot analysis. Western blot were performed as described previously (Beaulieu et al., 2004) . Briefly, mice were killed by decapitation, after which the heads of the animals were immediately cooled by immersion in liquid nitrogen for 6 s. The right hemistriatum was rapidly dissected out (within 30 s) on an ice-cold surface and frozen in liquid nitrogen before protein extraction. Tissue samples were homogenized in boiling 1% SDS solution supplemented with 2 M okadaic acid and boiled for 10 min. Protein concentration was measured by using a DC-protein assay (Bio-Rad, Hercules, CA). Protein extracts (25 or 50 g) were separated on 10% SDS-PAGE and transferred to nitrocellulose membranes. Blots were immunostained overnight at 4°C with the following primary antibodies: anti-phospho-GSK3/Ser-21/9 (1:200 dilution); anti-phospho-Akt Thr-308 (1:100); anti-phosphoAkt Ser-473 (1:500); anti-GSK3/clone 0011-A (1:5000); and anti-Akt (1:1000). Immune complexes were detected using appropriate peroxidase-conjugated secondary antibodies along with a chemiluminescent reagent (SuperSignal West-Pico; Pierce, Rockford, IL). Densitometric analysis was performed within linear range by using IMAGE-QUANT version 1.1 (GE Healthcare, Piscataway, NJ). Total protein signal was used as loading controls for phospho-proteins. Results are normalize to respective control conditions and presented as means Ϯ SEM. Data were analyzed by two-tailed t test. Anti-GSK3/clone 0011-A was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other primary antibodies were from Cell Signaling Technology (Beverly, MA). Secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA).
Results

Basal regulation of Akt and GSK3␤ in dopamine receptor knock-out mice
Western blot analysis of the relative levels of striatal phosphoThr-308 Akt showed no variation in Akt phosphorylation between D 1 -KO mice and WT littermates ( Fig. 1 A, E) , thus confirming previous pharmacological evidence (Beaulieu et al., 2004 ) that D 1 receptors play little role in inhibiting Akt activity under basal conditions. In contrast, elimination of either D 2 , D 2 L, or D 3 receptors in genetically engineered animals led to increased striatal Akt phosphorylation ( Fig. 1 B-E) . Furthermore, phosphorylation of the Akt substrate GSK3␤ was also enhanced in these mice ( Fig. 1 F) , indicating the both D 3 and the long postsynaptic D 2 isoform D 2 L can both contribute to the regulation of Akt/GSK3 signaling by DA.
Overall Akt activity is the result of an equilibrium between its phosphorylation/activation on Thr-308 and Ser-473 in response to phosphatidylinositol kinase (PI3K)-mediated signaling and its dephosphorylation by protein phosphatases. DA receptor signaling through the Akt:␤-arrestin 2:PP2A complex results in a dephosphorylation of Thr-308 Akt by PP2A without affecting its phosphorylation on Ser-473 (Beaulieu et al., 2004 (Beaulieu et al., , 2005 ). In contrast, changes in PI3K signaling affect the phosphorylation of both Thr-308 and Ser-473 in a similar manner (Beaulieu et al., 2005) . To further establish that changes of Akt phosphorylation observed in DA receptor KO mice result from impaired Akt deactivation by the Akt:␤-arrestin 2:PP2A complex and not from enhanced PI3K-mediated signaling, we evaluated relative levels of striatal phospho-Ser-473 Akt in the different DA receptor KO mice and respective littermates. As shown (Fig. 1G) , phosphoSer-473 levels were not increased in the different DA receptor KO mice, consistent with the enhanced Thr-308 phosphorylation in D 2 , D 2 L, and D 3 -KO mice resulting from a reduction in ␤-arrestin 2-mediated DA receptor signaling. Interestingly, Ser- , Phospho-Ser-9 GSK3␤ (F ) or phospho-Ser-473 Akt (G) levels in extracts prepared from the striatum of drug-naive DA receptor knock-out mice and WT littermates. Results are presented in arbitrary units normalized to phospho-protein levels observed in WT littermates. Phosphoindependent antibodies directed against respective kinases were used as loading controls. n ϭ 5-10 mice per group; data are average Ϯ SEM. *p Յ 0.05, ***p Յ 0.005.
473 Akt levels were reduced in D 2 -KO mice, suggesting unexplored additional roles of D 2 in Akt regulation.
D 4 receptor blockade does not affect striatal Akt regulation
To examine the possible contribution of D 4 receptors, we administered an effective dose of the selective D 4 receptor antagonist L745870 (Ukai and Mitsunaga, 2005) to WT animals. A similar experiment was also performed using DAT-KO mice that display a basal reduction of striatal phospho-Thr-308 Akt as a results of exacerbated dopaminergic neurotransmission (Beaulieu et al., 2004 (Beaulieu et al., , 2005 . DAT-KO mice have persistently increased extracellular dopamine and display high responsiveness to D 2 -class receptor antagonists and may thus represent a more sensitive experimental system to evaluate the impact of such drugs in vivo. As shown in Figure 2 , D 4 receptor blockade did not affect striatal Akt phosphorylation in either WT or DAT-KO mice.
Regulation of Akt by dopaminergic drugs in DA receptor knock-out mice
For the D 1 /D 2 -class DA receptor, the direct agonist apomorphine and the psychostimulant amphetamine, which acts by promoting DA efflux from dopaminergic terminals, both trigger Akt dephosphorylation in the WT mouse striatum (Beaulieu et al., 2004 (Beaulieu et al., , 2005 . Administration of apomorphine (3 mg/kg, s.c.) or amphetamine (3 mg/kg, i.p.) to WT or D 1 -KO mice resulted in a similar reduction of phospho-Thr-308 Akt levels (Fig. 3A-D) , thus further confirming that D 1 receptors are dispensable for Akt inhibition in response to dopaminergic drugs.
In contrast, administration of apomorphine (3 mg/kg, s.c.) or amphetamine (3 mg/kg, i.p.) to mice lacking D 2 receptors failed to reduce striatal Akt phosphorylation (Fig. 3A-D) . Instead, apomorphine at a dose of 3 mg/kg significantly enhanced the phosphorylation of Akt in the absence of D 2 receptors (Fig. 3B) , whereas amphetamine had no significant effect on Akt in D 2 -KO mice (Fig. 3D) . Activation of Akt by apomorphine in the absence of D 2 probably resulted from the unmasking of a secondary action of this drug on another receptor(s) that may positively regulate Akt in the striatum (Roth et al., 2004) . These observations reveal a central role for D 2 receptors in the inhibition of Akt because the remaining striatal DA receptors are not able to mediate the inhibitory action of dopaminergic drugs on this signaling molecule in D 2 -KO mice.
Injection of 3 mg/kg amphetamine to D 3 -KO mice resulted in reductions of striatal Akt phosphorylation similar to those observed in WT animals (Fig. 4 A, B) . However, elimination of D 3 receptors prevented Akt dephosphorylation in response to a dose of 3 mg/kg apomorphine (Fig. 4 E, F ) . This discrepancy between the effects of the two drugs led us to explore the action of apomorphine and amphetamine on Akt in D 3 -KO mice over a broader range of doses. As shown in Figure 4 , C and D, injection of amphetamine at a dose of 1 mg/kg reduced Akt phosphorylation in the striatum of WT mice but had no effect on Akt activity in D 3 -KO animals. Furthermore, administration of apomorphine to D 3 -KO mice at a dose of 6 mg/kg resulted in a reduction of striatal Akt phosphorylation comparable with that observed in WT animals in response to a lower dose (3 mg/kg) of this drug (Fig. 4 E, F ) . Together, these observations indicate that D 3 receptors may play a role in regulating the sensitivity of Akt-mediated signaling to dopaminergic drugs but are dispensable for the action of these drugs on Akt at higher dose regimens.
Discussion
Multiple recent lines of evidence identified an involvement of the Akt/GSK3 pathway in DA receptor signaling and functions (Beaulieu et al., 2004 (Beaulieu et al., , 2005 Emamian et al., 2004; Gould and Manji, 2005; Beaulieu, 2007) . Genetic inactivation of Akt1 or GSK3␤, administration of GSK3 inhibitors, or uncoupling of Akt from dopamine receptors in ␤-arrestin 2 knock-out mice have been shown to affect DA-related changes in locomotor activity or sensory motor gating (Beaulieu et operidol and raclopride have pointed toward a role of this DA receptor class in the regulation of Akt-mediated signaling (Beaulieu et al., 2004; Emamian et al., 2004) . However, the role of individual subtypes of DA receptors in triggering Akt dephosphorylation in dopaminoceptive neurons had not been fully examined. The results presented here reveal that two subtypes of D 2 -class receptors, D 2 and D 3 , are involved in the inhibition of Akt by DA and dopaminergic drugs in the mouse striatum, whereas D 4 dopamine receptors do not appear to play a role in this phenomena. Furthermore, these data clearly establish that D 1 dopamine receptors are not engaged in this type of signaling.
Genetic inactivation of total D 2 or of the postsynaptic D 2 L receptors led to enhanced Akt phosphorylation in the striatum of knock-out mice. Furthermore, absence of D 2 receptors also resulted in a loss of normal striatal Akt regulation by dopaminergic drugs. D 2 receptors exert both presynaptic and postsynaptic functions. In their presynaptic autoreceptor function, mediated by the D 2 S isoform, these receptors are responsible for the regulation of DA synthesis and, consequently, impulse-dependent dopamine release (Baik et al., 1995; Missale et al., 1998; Usiello et al., 2000; Benoit-Marand et al., 2001) . Postsynaptic D 2 receptors have been associated with, among other effects, stimulation of locomotion and the development of haloperidol-induced catalepsy (Baik et al., 1995; Usiello et al., 2000) . A loss of D 2 autoreceptor function thus should result in an increase of DA synthesis and, consequently, release (Benoit-Marand et al., 2001) , which would in turn lead to a reduction in striatal Akt phosphorylation as demonstrated in DAT-KO and amphetamine-treated WT mice (Beaulieu et al., 2004 (Beaulieu et al., , 2005 . However, the increased basal Akt phosphorylation in D 2 -KO as well as in D 2 L-KO mice, which do not display major changes in D 2 autoreceptor function (Usiello et al., 2000) , indicate that the negative regulation of Akt by DA is mostly a postsynaptic phenomena regulated by D 2 receptors.
Like D 2 , D 3 receptors are believed to exert their actions both presynaptically and postsynaptically (Missale et al., 1998; Schwartz et al., 2000; Joseph et al., 2002) . However, despite multiple associations between D 3 receptors and different neuropsychiatric disorders (Schwartz et al., 2000) , knock-out studies have yet to produce a clear picture of the behavioral and neurochemical functions mediated by these receptors (Ralph et al., 1999; Joseph et al., 2002; Waddington et al., 2005) . Our results suggest that D 3 receptors act as modulators that affect the threshold at which Akt is regulated by D 2 receptors. At relatively high drug doses (e.g., 3 mg/kg amphetamine or 6 mg/kg apomorphine), D 3 receptors are dispensable and D 2 receptors can regulate Akt dephosphorylation in their absence. However, at lower drug doses or under basal conditions, D 3 receptors may also contribute to the negative regulation of Akt activity by D 2 receptors.
Studies conducted in heterologous systems have shown that D 3 receptors possess an affinity for DA that is 100-fold higher than that of D 2 receptors (Sokoloff et al., 1992) . This difference in affinity may explain why D 3 receptors can respond to lower doses of dopaminergic drugs and regulate Akt activity. However, this explanation does not account for the inability of D 3 receptors to modulate Akt activity in the absence of D 2 . Several possible scenarios can explain the observation that DA inhibition of Akt is dependent on D 2 receptors and only modulated by D 3 receptors. It is known that GPCRs can function as dimers (Angers et al., 2002) , and one potential mechanism to explain this conundrum is the possibility of dimerization of D 2 and D 3 dopamine receptors expressed in the same medium spiny neurons. Our results are consistent with the idea that Akt may be regulated by D 2 /D 2 homodimers as well as by D 2 /D 3 heterodimers in which D 3 would provide a higher affinity for DA receptor agonists, allowing D 2 to inhibit Akt in response to lower drug doses. However, this explanation remains hypothetical, and other possibilities such as an integration of D 2 and D 3 receptors signal at the level of Akt or other signaling intermediates cannot be excluded. Another alternative is that, because our results are derived from a biochemical approach on the whole striatum, the readout coming from a higher number of cells expressing D 2 receptors may also mask a possible D 2 -independent action of D 3 receptors in some individuals cells. Characterization of the detailed mechanism by which D 2 and D 3 DA receptors collaborate to inhibit Akt will certainly require protracted studies in vivo, in isolated neurons, as well as in heterologous systems and should provide an exciting avenue for future research.
The Akt/GSK3 signaling pathway has recently emerged as a potential culprit and therapeutic target for psychiatric disorders (Beaulieu et al., 2004 (Beaulieu et al., , 2005 Emamian et al., 2004; Gould and Manji, 2005; Beaulieu, 2007; Li et al., 2007) . Brain Akt/GSK3 signaling has been shown to be responsive to DA (Beaulieu et al., 2004 (Beaulieu et al., , 2005 , typical/atypical antipsychotics (Emamian et al., 2004; Beaulieu, 2007; Li et al., 2007) , antidepressants (Li et al., 2007) , and mood stabilizers (Beaulieu et al., 2004; Gould and Manji, 2005; Beaulieu, 2006) . Moreover, deregulation of Akt functions have been reported in schizophrenia (Emamian et al., 2004) . Interestingly, D 2 and D 3 receptors have been linked previously to schizophrenia (Snyder, 1976; Schwartz et al., 2000) , whereas D 3 has also been associated with some cases of bipolar disorder (Schwartz et al., 2000) . Our present observations that both D 2 and D 3 receptors can contribute to the regulation of Akt in vivo may thus be important for the development of more selective pharmaceutical interventions for the management of mental disorders associated with dopaminergic deregulation.
